Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

434 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC; ELIXA Investigators. Pfeffer MA, et al. Among authors: gerstein hc. N Engl J Med. 2015 Dec 3;373(23):2247-57. doi: 10.1056/NEJMoa1509225. N Engl J Med. 2015. PMID: 26630143 Free article. Clinical Trial.
Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure.
Yusuf S, Ostergren JB, Gerstein HC, Pfeffer MA, Swedberg K, Granger CB, Olofsson B, Probstfield J, McMurray JV; Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators. Yusuf S, et al. Among authors: gerstein hc. Circulation. 2005 Jul 5;112(1):48-53. doi: 10.1161/CIRCULATIONAHA.104.528166. Epub 2005 Jun 27. Circulation. 2005. PMID: 15983242 Clinical Trial.
Effect of ramipril on the incidence of diabetes.
DREAM Trial Investigators; Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR. DREAM Trial Investigators, et al. Among authors: gerstein hc. N Engl J Med. 2006 Oct 12;355(15):1551-62. doi: 10.1056/NEJMoa065061. Epub 2006 Sep 15. N Engl J Med. 2006. PMID: 16980380 Free article. Clinical Trial.
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.
ACCORD Study Group; Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, Grimm RH Jr, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD. ACCORD Study Group, et al. Among authors: gerstein hc. Am J Cardiol. 2007 Jun 18;99(12A):21i-33i. doi: 10.1016/j.amjcard.2007.03.003. Epub 2007 Apr 16. Am J Cardiol. 2007. PMID: 17599422 Clinical Trial.
Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention).
Origin Trial Investigators; Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J. Origin Trial Investigators, et al. Am Heart J. 2008 Jan;155(1):26-32, 32.e1-6. doi: 10.1016/j.ahj.2007.09.009. Epub 2007 Nov 26. Am Heart J. 2008. PMID: 18082485 Clinical Trial.
Effects of intensive glucose lowering in type 2 diabetes.
Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Action to Control Cardiovascular Risk in Diabetes Study Group, et al. Among authors: gerstein hc. N Engl J Med. 2008 Jun 12;358(24):2545-59. doi: 10.1056/NEJMoa0802743. Epub 2008 Jun 6. N Engl J Med. 2008. PMID: 18539917 Free PMC article. Clinical Trial.
The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program.
Gerstein HC, Swedberg K, Carlsson J, McMurray JJ, Michelson EL, Olofsson B, Pfeffer MA, Yusuf S; CHARM Program Investigators. Gerstein HC, et al. Arch Intern Med. 2008 Aug 11;168(15):1699-704. doi: 10.1001/archinte.168.15.1699. Arch Intern Med. 2008. PMID: 18695086 Clinical Trial.
Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program.
Preiss D, Zetterstrand S, McMurray JJ, Ostergren J, Michelson EL, Granger CB, Yusuf S, Swedberg K, Pfeffer MA, Gerstein HC, Sattar N; Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity Investigators. Preiss D, et al. Among authors: gerstein hc. Diabetes Care. 2009 May;32(5):915-20. doi: 10.2337/dc08-1709. Epub 2009 Feb 5. Diabetes Care. 2009. PMID: 19196892 Free PMC article.
434 results